In a new study, OHSU researchers have found that individuals receiving a COVID-19 vaccine during the first half of their menstrual cycle are more likely to experience slight, temporary cycle length changes than those receiving a vaccine in the second half. The study's lead author, Alison Edelman, M.D., says: "Understanding these changes on a population level allows us to more effectively counsel patients about what to expect with a COVID-19 vaccine. We hope this work helps validate the public’s experiences and ease fears and anxiety around vaccination."

In a USA Today article on the power of male friendship, citing celebrities Ben Affleck and Matt Damon as an example, Chris Reigeluth, Ph.D., says: "They are very open about just how much they care about one another, and loving one another and how important that relationship is to them."

An innovative OHSU research program that enlists older Black adults to walk through and reminisce about historically Black neighborhoods in Portland may help improve cognitive function, a new study finds. The study's lead author Raina Croff, Ph.D., says "Overall, those with memory loss did improve, and the average improvement was statistically significant."

In a new study, OHSU researchers find individuals receiving a COVID-19 vaccine during the first half of their menstrual cycle are more likely to experience slight, temporary cycle length changes than those receiving a vaccine in the second half. The study's lead author, Alison Edelman, M.D., says: "Understanding these changes on a population level allows us to more effectively counsel patients about what to expect with a COVID-19 vaccine. We hope this work helps validate the public’s experiences and ease fears and anxiety around vaccination."

A National Public Radio story on psilocybin treatment centers in Oregon references the Oregon Psilocybin Evaluation Nexus, a research cooperative housed at OHSU to "further research and standardization of evaluation and information sharing, trying to systematize the very definitions used in reporting, and building the tools for doing so." Daniel Nicoli, D.O., says, “We’re certainly not saying we don’t want psilocybin to be medicine. We’re just saying we want the research in place.”

Saurabh Thosar, Ph.D., discusses the risk for cardiovascular and blood clot issues in video game players such as e-sports athletes.

New OHSU research for the first time reveals the function of a little-understood junction between cells in the brain that could have important treatment implications for conditions ranging from multiple sclerosis to Alzheimer’s disease to a type of brain cancer known as glioma.

In a HealthDay article on the U.S. Preventive Services Task Force saying there is insufficient evidence on screening and supplementation for iron deficiency anemia during pregnancy, a systematic review led by Amy Cantor, M.D., is mentioned.

Robert Cloutier, M.D., offers advice to University of Oregon undergrad students who plan to apply to medical schools and describes the OHSU School of Medicine admissions process. Cloutier says he enjoys helping medical students grow and advance: “For some people, it’s a long road to get to medical school and I’ve had people who still text me today, thanking me for letting them into medical school, especially students who come from underprivileged backgrounds, and for whom they’re first-generation college, these are big, big moments for them.”

A BioSpace article on the importance of patient advocacy in drug development for rare diseases features the work by Shivaani Kummar, M.D., and the Desmoid Tumor Research Foundation to organize and recruit patients for a Phase II clinical trial of a now FDA-approved drug while Kummar was at the National Cancer Institute. Kummar worked with the foundation to recruit enough patients with the rare disease.